IL325052A - תאי t משוריינים - Google Patents

תאי t משוריינים

Info

Publication number
IL325052A
IL325052A IL325052A IL32505225A IL325052A IL 325052 A IL325052 A IL 325052A IL 325052 A IL325052 A IL 325052A IL 32505225 A IL32505225 A IL 32505225A IL 325052 A IL325052 A IL 325052A
Authority
IL
Israel
Prior art keywords
cancer
cells
population
car
cell
Prior art date
Application number
IL325052A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL325052A publication Critical patent/IL325052A/he

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/30Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31Chimeric antigen receptors [CAR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL325052A 2023-06-06 2024-06-05 תאי t משוריינים IL325052A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363506586P 2023-06-06 2023-06-06
PCT/IB2024/055504 WO2024252305A1 (en) 2023-06-06 2024-06-05 Armored t cells

Publications (1)

Publication Number Publication Date
IL325052A true IL325052A (he) 2026-02-01

Family

ID=91581947

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325052A IL325052A (he) 2023-06-06 2024-06-05 תאי t משוריינים

Country Status (8)

Country Link
EP (1) EP4724089A1 (he)
KR (1) KR20260021025A (he)
CN (1) CN121240873A (he)
AU (1) AU2024285571A1 (he)
IL (1) IL325052A (he)
MX (1) MX2025014741A (he)
TW (1) TW202511490A (he)
WO (1) WO2024252305A1 (he)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024000112A (es) * 2021-06-30 2024-06-19 New York Genome Center Inc Metodos y composiciones para inmunoterapias mejoradas.
US20230279352A1 (en) 2021-08-24 2023-09-07 Astrazeneca Ab Methods for generating primary immune cells

Also Published As

Publication number Publication date
CN121240873A (zh) 2025-12-30
TW202511490A (zh) 2025-03-16
MX2025014741A (es) 2026-02-03
AU2024285571A1 (en) 2026-01-22
EP4724089A1 (en) 2026-04-15
WO2024252305A1 (en) 2024-12-12
KR20260021025A (ko) 2026-02-12

Similar Documents

Publication Publication Date Title
US12404314B2 (en) Switch costimulatory receptors
CN113661180B (zh) Tn-MUC1嵌合抗原受体(CAR)T细胞疗法
US12152079B2 (en) Nucleic acids encoding IL-13 receptor alpha 2 (IL13Ra2) chimeric antigen receptor for tumor specific T cell immunotherapy
AU2015335029B2 (en) Combination
CN111601823B (zh) 用car-t或car-nk细胞在癌症治疗中靶向lilrb4
ES2876925T3 (es) Receptores de antígeno quiméricos específicos para ROR1 (NTRKR1) para inmunoterapia contra el cáncer
JP2023081935A (ja) がん免疫療法のための組成物および方法
TWI912312B (zh) 用嵌合抗原受體治療癌症之組成物及方法
CN119925616A (zh) Cd20疗法、cd22疗法和与cd19嵌合抗原受体(car)表达细胞的联合疗法
JP2024537176A (ja) ナチュラルキラー細胞及びその使用方法
JP2023505925A (ja) バリアント型インターロイキン-2(vIL-2)ポリペプチドをコードする腫瘍溶解性ウイルスベクター
CN114630683A (zh) 包含痘苗病毒和粒细胞生成抑制剂作为活性成分的用于治疗癌症的药物组合物
CN117247466A (zh) 抗磷脂酰肌醇蛋白聚糖3的嵌合抗原受体及其用途
AU2024285571A1 (en) Armored t cells
KR102809807B1 (ko) 항-cldn18.2를 포함하는 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법
KR20240012413A (ko) 폐암 치료를 위한 조성물 및 방법
KR102739632B1 (ko) 항-cd20 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법
WO2020097236A1 (en) Fgl2 neutraling cell therapy and methods of use thereof
CN111629737A (zh) T细胞信号传导的miRNA调节及其应用
US20230295564A1 (en) Galectin-9 Specific Binding Agents for Use in Treating Cancer
WO2025133213A1 (en) Death receptor 5 (dr5)-armored car-t therapeutic
CN121362259A (zh) 新型PDL1-CAR-γδT细胞的构建及其抗肿瘤应用
HK40110020A (zh) 自然杀伤细胞及其使用方法
IL324320A (he) תאי קטל טבעיים מרובי קולטנים